$1.32
4.76% yesterday
Nasdaq, Sep 27, 10:16 pm CET
ISIN
US68217N1054
Symbol
OMGA
Sector
Industry

Omega Therapeutics Inc Stock price

$1.32
-0.15 10.20% 1M
-2.23 62.82% 6M
-1.69 56.15% YTD
-0.93 41.33% 1Y
-17.68 93.05% 3Y
-14.68 91.75% 5Y
-14.68 91.75% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.06 4.76%
ISIN
US68217N1054
Symbol
OMGA
Sector
Industry

Key metrics

Market capitalization $69.50m
Enterprise Value $150.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 23.81
P/S ratio (TTM) P/S ratio 11.01
P/B ratio (TTM) P/B ratio 2.65
Revenue growth (TTM) Revenue growth 142.38%
Revenue (TTM) Revenue $6.31m
EBIT (operating result TTM) EBIT $-80.63m
Free Cash Flow (TTM) Free Cash Flow $-67.37m
Cash position $46.19m
EPS (TTM) EPS $-1.43
P/E forward negative
P/S forward 10.06
EV/Sales forward 21.75
Short interest 29.05%
Show more

Is Omega Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Omega Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Omega Therapeutics Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Omega Therapeutics Inc forecast:

Buy
100%

Financial data from Omega Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
6.31 6.31
142% 142%
100%
- Direct Costs 6.07 6.07
5% 5%
96%
0.24 0.24
108% 108%
4%
- Selling and Administrative Expenses 14 14
8% 8%
229%
- Research and Development Expense 60 60
34% 34%
957%
-75 -75
31% 31%
-1,182%
- Depreciation and Amortization 6.07 6.07
5% 5%
96%
EBIT (Operating Income) EBIT -81 -81
29% 29%
-1,278%
Net Profit -79 -79
29% 29%
-1,250%

In millions USD.

Don't miss a Thing! We will send you all news about Omega Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omega Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega's approach to precis...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the addition of Jennifer Nelson, Ph.D., to the Company's executive leadership team in the role of Senior Vice President of Research. She brings over 20 years of experien...
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.
More Omega Therapeutics Inc News

Company Profile

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting, mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Mahesh Karande
Employees 94
Founded 2016
Website www.omegatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today